SciELO - Scientific Electronic Library Online

vol.47 número1Medidas de bioseguridad adoptadas en el manejo con materiales biológicos en Laboratorios LioradEfecto sobre la viabilidad celular de una nueva serie de espirosteroides sintéticos en células PC12 índice de autoresíndice de materiabúsqueda de artículos
Home Pagelista alfabética de revistas  

Servicios Personalizados




  • No hay articulos citadosCitado por SciELO

Links relacionados

  • No hay articulos similaresSimilares en SciELO


Revista Cubana de Farmacia

versión impresa ISSN 0034-7515


NODARSE-CUNI, Hugo et al. Epidermal growth factor enemas for induction of remission in left-sided ulcerative colitis. Rev Cubana Farm [online]. 2013, vol.47, n.1, pp.67-76. ISSN 0034-7515.

Introduction: ulcerative colitis is a little known chronic inflammatory disease in colonic mucosa. The positive effect of epidermal growth factor was shown in a previous report, with enema use for treatment of mild to moderate left-sided manifestation of the disease. This evidence provided the basis for evaluating the efficacy and safety profile of a viscous solution of this product. Methods: thirty-one patients were randomized to three groups for daily medications during 14 days. Twelve received one 10 mg enema of epidermal growth factor dissolved in 100 mL of viscous solution whereas nine were treated with placebo enema; both groups also received 1.2 g of oral mesalamine per day. The other group included ten patients with 3 g / 100 mL of mesalamine enema. Primary end point was clinical responses after two weeks of treatment, defined as a decreased of, at least three points from baseline, the Disease Activity Index and endoscopic or histological evidences of improvement. Results: remission of disease was observed in all patients in the epidermal growth factor group, and six in both, mesalamine enema and placebo group. All the comparisons between groups showed statistically significant superiority for epidermal growth factor, the only product with significant reduction in disease activity index as well as the presence and intensity of digestive symptoms in patients after treatment. None adverse event was reported. Conclusions: the results agree with previous molecular and clinical evidences, indicating that the epidermal growth factor is effective to reduce disease activity and to induce remission. A new study involving more patients should be conducted to confirm the efficacy of the epidermal growth factor enemas.

Palabras clave : Ulcerative colitis; Epidermal Growth Factor; Mesalamine; Clinical trial.

        · resumen en Español     · texto en Inglés     · Inglés ( pdf )